Gedeon Richter (RICHTER) Q3 2025 earnings summary

Executive summary

• Q1–Q3 2025 revenue grew 7% year-over-year to HUF 669bn, with strong performance in Women's Healthcare and CNS, but Q3 slowed due to FX headwinds and GenMed/CDMO challenges.

• Clean EBIT rose 7% year-over-year to HUF 213bn for Q1–Q3, but declined 7% in Q3, mainly due to GenMed headwinds and wider BIO losses.

• Net profit for Q1–Q3 was HUF 163.3bn, down 7% year-over-year, as FX losses and higher tax offset operating gains.

• Temporary revenue slowdown in Q3 is expected to recover gradually, with full normalization in GenMed supply by Q1 2026.

• Efficiency programs and cost controls helped mitigate profitability impact from weaker top line.

Financial highlights

• Nominal growth close to 7% year-to-date, with FX-adjusted growth slightly lower; gross profit (pharma) grew 6% YoY to HUF 463bn in Q1–Q3.

• Clean EBIT for Q3 was HUF 66bn, down 7% year-over-year, but year-to-date Clean EBIT up 7% to HUF 213bn.

• Free cash flow reached an all-time high of HUF 200bn for the first nine months, up 22% year-over-year.

• EPS for Q1–Q3 was HUF 893, down 6.9% year-over-year; return on equity was 17.0%, down 0.3ppt YoY.

• Significant FX losses of HUF 24.7bn compared to gains last year, and higher taxes due to global minimum tax regime and deferred tax from acquisitions.

Outlook and guidance

• Full-year revenue at constant exchange rate expected to approach EUR 2.3bn, at the lower end of previous guidance.

• Clean EBIT growth for the full year projected at 8%-10% at constant exchange rates.

• Q4 expected to show double-digit quarter-on-quarter and year-over-year growth, with most Q3 headwinds seen as one-off.

• Regular dividend increases anticipated, in line with capital allocation framework.